Pharma BD Deal Intelligence
The lead asset (BIVV009/Enjaymo) eventually became a real, approved niche drug — but hit a 2020 FDA rejection first, and Sanofi (which inherited it via the 2018 Bioverativ buyout) ultimately sold it off entirely to Recordati in 2024 rather than keep it.
Full analysis, sources & comparables →Cast the True North buy as Bioverativ's first M&A move post-Biogen spinout, signaling a broader rare-disease strategy beyond hemophilia and citing…
Confirmed deal close on June 28, 2017 and reiterated the strategic rationale of broadening the rare-blood-disorder pipeline into complement-mediated diseases.
Announced FDA approval of Enjaymo (sutimlimab-jome) as the first and only treatment for hemolysis in adults with cold agglutinin disease, validating the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Bioverativ agreed to acquire clinical-stage rare disease biotech True North Therapeutics for $400M upfront cash plus up to $425M in development, regulatory and sales milestones (~$825M total). The lead asset BIVV009 (later sutimlimab) is a first-in-class anti-C1s antibody for cold agglutinin disease. Closed June 2017.
The lead asset (BIVV009/Enjaymo) eventually became a real, approved niche drug — but hit a 2020 FDA rejection first, and Sanofi (which inherited it via the 2018 Bioverativ buyout) ultimately sold it off entirely to Recordati in 2024 rather than keep it.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bioverativ Inc. / True North Therapeutics, Inc. (this deal) | 2017 | $825M | 57 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2017 deals · Hematology deals